Description of Medical ServiceThe medical service is for the testing of tumour tissue to determine HRD status. The HRD test involves the next generation sequencing (NGS) of DNA from a biopsy or preserved specimens (archived FFPE block) of tumour tissue. An assay detects how your body repairs double strand breaks in DNA, which is constantly being damaged and repaired. When DNA is repaired, the process is called homologous recombination. HRD positive means your body is unable to effectively repair these double strand breaks in the DNA. HRD can include a number of genes, including BRCA1 and BRCA1 genes.
Description of Medical ConditionOvarian cancer is a diverse disease comprising different subtypes. The majority of ovarian cancers are of epithelial origin, with most classified as high-grade tumours. Early symptoms are often nonspecific, such as pelvic or abdominal discomfort, bloating, difficulty eating or feeling full and urinary urgency or frequency. Most patients are therefore diagnosed at an advanced stage (Stage 3 and 4) when prominent symptoms such as ascites (fluid build-up in spaces within the abdomen) and abdominal masses are evident.
Reason for ApplicationNew MBS item
Medical Service TypeInvestigative – PBAC codependent application
Previous Application Number/sNot Applicable
Application FormApplication Form (PDF 1659 KB)
Application Form (Word 475 KB)
Consultation SurveyConsultation Survey (PDF 659 KB)
Consultation Survey (Word 27 KB)
Expedited – Bypassing PASC
MSAC consultation input must be received by no later than Friday, 10 February 2023 for it to be considered by MSAC at its March 2023 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process